X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs DR. REDDYS LAB - Comparison Results

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA DR. REDDYS LAB PLETHICO PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x -1.1 31.8 - View Chart
P/BV x 0.0 3.4 0.5% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 PLETHICO PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
DR. REDDYS LAB
Mar-18
PLETHICO PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs3952,788 14.2%   
Low Rs311,902 1.6%   
Sales per share (Unadj.) Rs604.4860.8 70.2%  
Earnings per share (Unadj.) Rs32.557.1 56.9%  
Cash flow per share (Unadj.) Rs51.3122.0 42.1%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs473.6757.7 62.5%  
Shares outstanding (eoy) m34.08165.91 20.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.42.7 12.9%   
Avg P/E ratio x6.641.1 16.0%  
P/CF ratio (eoy) x4.219.2 21.6%  
Price / Book Value ratio x0.53.1 14.5%  
Dividend payout %035.0 0.0%   
Avg Mkt Cap Rs m7,262389,034 1.9%   
No. of employees `000NA23.5 0.0%   
Total wages/salary Rs m1,59632,149 5.0%   
Avg. sales/employee Rs ThNM6,070.8-  
Avg. wages/employee Rs ThNM1,366.6-  
Avg. net profit/employee Rs ThNM402.5-  
INCOME DATA
Net Sales Rs m20,598142,810 14.4%  
Other income Rs m3861,552 24.9%   
Total revenues Rs m20,984144,362 14.5%   
Gross profit Rs m2,81823,512 12.0%  
Depreciation Rs m64210,772 6.0%   
Interest Rs m1,593788 202.2%   
Profit before tax Rs m96913,504 7.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m0344 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1384,380 -3.2%   
Profit after tax Rs m1,1079,468 11.7%  
Gross profit margin %13.716.5 83.1%  
Effective tax rate %-14.332.4 -44.1%   
Net profit margin %5.46.6 81.1%  
BALANCE SHEET DATA
Current assets Rs m18,877104,984 18.0%   
Current liabilities Rs m11,89668,938 17.3%   
Net working cap to sales %33.925.2 134.3%  
Current ratio x1.61.5 104.2%  
Inventory Days Days3674 48.3%  
Debtors Days Days198104 191.0%  
Net fixed assets Rs m9,861104,385 9.4%   
Share capital Rs m341830 41.0%   
"Free" reserves Rs m12,331124,886 9.9%   
Net worth Rs m16,139125,716 12.8%   
Long term debt Rs m4,70625,089 18.8%   
Total assets Rs m33,146225,443 14.7%  
Interest coverage x1.618.1 8.9%   
Debt to equity ratio x0.30.2 146.1%  
Sales to assets ratio x0.60.6 98.1%   
Return on assets %8.14.5 179.1%  
Return on equity %6.97.5 91.1%  
Return on capital %12.39.7 126.6%  
Exports to sales %21.40-   
Imports to sales %15.20-   
Exports (fob) Rs m4,402NA-   
Imports (cif) Rs m3,136NA-   
Fx inflow Rs m4,40272,623 6.1%   
Fx outflow Rs m3,18418,916 16.8%   
Net fx Rs m1,21953,707 2.3%   
CASH FLOW
From Operations Rs m2,43718,030 13.5%  
From Investments Rs m-6,265-14,883 42.1%  
From Financial Activity Rs m2,490-4,440 -56.1%  
Net Cashflow Rs m-1,337-1,236 108.2%  

Share Holding

Indian Promoters % 82.7 25.5 324.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 5.4 79.6%  
FIIs % 5.5 35.3 15.6%  
ADR/GDR % 0.0 18.5 -  
Free float % 7.5 15.3 49.0%  
Shareholders   10,665 75,885 14.1%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   PFIZER  GSK PHARMA  PANACEA BIOTECH  WYETH LTD  ABBOTT INDIA  

Compare PLETHICO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 5-YR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS